ArticleHypertension research : official journal of the Japanese Society of Hypertension2025
Human plasma metabolomics reveals metabolic targets for intervention in salt-sensitive hypertension.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salt-sensitive hypertension (SSH) is a major risk factor for cardiovascular disease, but its metabolic mechanisms remain unclear. This study investigates the plasma metabolic profile of SSH patients to identify potential therapeutic targets. Additionally, SSH patients were identified through an oral salt-loading test. Plasma metabolomics was performed by utilizing GC-MS and LC-MS, followed by network correlation analysis, pathway enrichment, receiver operating characteristic analysis, and linear regression analysis. The findings were validated in Dahl salt-sensitive (SS) rats, with glycine supplementation evaluated as a potential therapeutic intervention. Firstly, plasma metabolomics illustrated distinct metabolic alterations in SSH patients, with substantially increased levels of fumaric acid, pyruvat,e and lactic acid, as well as significantly decreased levels of glycine, leucine and β-alanine (p < 0.05). Additionally, Glycine and β-alanine levels decreased by 61% and 68% compared to the control group. Secondly, pathway enrichment analysis identified disruptions in amino acid metabolism, particularly Arginine biosynthesis pathway, TCA pathway, glycine, serine, and threonine metabolism pathways were significantly enriched (p < 0.05). Correlation network analysis identified fumarate as a hub metabolite in the pathophysiology of SSH. Glycine showed the highest predictive value for SSH (AUC = 94.6181%) and was negatively correlated with blood pressure. Finally, glycine supplementation in SS rats substantially reduced salt-induced hypertension (p < 0.001) by improving renal amino acid metabolism and enhancing nitric oxide production. This study identifies glycine as a crucial metabolic target for SSH intervention. Glycine supplementation effectively alleviates SSH in animal models, indicating its potential for clinical applications. Future research should focus on exploring glycine-based therapies in clinical trials. Intervention targets and validation of salt-sensitive hypertension.
Indexed as
Identifiers
40731078What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.